Polymodal Mechanism for TWIK-Related K+ Channel Inhibition by Local Anesthetic

Anesth Analg. 2019 Oct;129(4):973-982. doi: 10.1213/ANE.0000000000004216.

Abstract

Background: Local anesthetics cause reversible block of pain and robustly inhibit TWIK-related K channel (TREK-1) currents. Before local anesthesia onset, injection of local anesthetics can cause unwanted transient pain. TREK-1 is an anesthetic-sensitive potassium channel that when inhibited produces pain. A disordered C-terminal loop of TREK-1 is thought to contribute to anesthetic sensitivity, but the molecular basis for TREK-1 inhibition by local anesthetics is unknown. Phospholipase D2 (PLD2) is an enzyme that produces phosphatidic acid (PA) required for TREK-1 activation and also binds to the channel's C terminus.

Methods: Here, we use biophysical and cellular techniques to characterize direct and indirect lipid-mediated mechanism for TREK-1 inhibition (respectively). We characterized direct binding of local anesthetic to TREK-1 by reconstituting the purified channel into artificial membranes and measuring ion flux. We characterized indirect PA-mediated inhibition of TREK-1 by monitoring lipid production in live whole cells using a fluorescent PLD2 product release assay and ion channel current using live whole-cell patch-clamp electrophysiology. We monitored anesthetic-induced nanoscale translocation of PLD2 to TREK-1 channels with super-resolution direct stochastic reconstruction microscopy (dSTORM).

Results: We find local anesthetics tetracaine, lidocaine, and bupivacaine directly bind to and inhibit PLD2 enzymatic activity. The lack of PLD2 activity indirectly inhibited TREK-1 currents. Select local anesthetics also partially blocked the open pore of TREK-1 through direct binding. The amount of pore block was variable with tetracaine greater than bupivacaine and lidocaine exhibiting a minor effect. Local anesthetics also disrupt lipid rafts, a mechanism that would normally activate PLD2 were it not for their direct inhibition of enzyme catalysis.

Conclusions: We propose a mechanism of TREK-1 inhibition comprised of (1) primarily indirect PLD2-dependent inhibition of lipid catalysis and (2) limited direct inhibition for select local anesthetics through partial open pore block. The inhibition through PLD2 explains how the C terminus can regulate the channel despite being devoid of structure and putative binding sites for local anesthetics.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Anesthetics, Local / pharmacology*
  • Animals
  • Bupivacaine / pharmacology*
  • CHO Cells
  • Cell Line, Tumor
  • Cricetulus
  • HEK293 Cells
  • Humans
  • Ion Channel Gating / drug effects
  • Lidocaine / pharmacology*
  • Membrane Microdomains / drug effects
  • Membrane Microdomains / metabolism
  • Phosphatidic Acids / metabolism
  • Phosphodiesterase Inhibitors / pharmacology*
  • Phospholipase D / antagonists & inhibitors*
  • Phospholipase D / genetics
  • Phospholipase D / metabolism
  • Potassium Channel Blockers / pharmacology*
  • Potassium Channels, Tandem Pore Domain / antagonists & inhibitors*
  • Potassium Channels, Tandem Pore Domain / genetics
  • Potassium Channels, Tandem Pore Domain / metabolism
  • Protein Interaction Domains and Motifs
  • Tetracaine / pharmacology*

Substances

  • Anesthetics, Local
  • Phosphatidic Acids
  • Phosphodiesterase Inhibitors
  • Potassium Channel Blockers
  • Potassium Channels, Tandem Pore Domain
  • potassium channel protein TREK-1
  • Tetracaine
  • Lidocaine
  • phospholipase D2
  • Phospholipase D
  • Bupivacaine